Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2003 March; 4(1): 27–32.
Published online 2003 January 21. doi:  10.1208/pt040104
PMCID: PMC2750300

Effect of heating temperature and time on pharmaceutical characteristics of albumin microspheres containing 5-fluorouracil


In this study, we found that both heating temperature and heating time affect mean particle size, particle size distribution, and drug entrapment efficiency of albumin microspheres. The change in heating temperature may affect the particle size of the product, especially when heating is carried out at a lower temperature (90°C–120°C). Hence the temperature should be selected on the basis of desired size range. Given that it is desirable for a maximum amount of the drug used in the preparation to become entrapped in microspheres, heating temperature and heating time for denaturation of albumin should be selected cautiously, as both have a significant effect on drug entrapment efficiency. In the present case, the highest entrapment was found in batches prepared by heating at 90°C for 5 minutes. However, the extent of stabilization at the selected temperature and the time of heating should also be taken into consideration, as they may affect the release of drugs to target tissue.

Full Text

The Full Text of this article is available as a PDF (55K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Kato T. Encapsulated drug in targeted cancer therapy. In: Bruck SD, editor. Controlled Drug Delivery. Vol 2. Clinical Applications. Boca Raton, Florida: CRC Press; 1983. pp. 189–240.
2. Truter EJ. Heat-stabilized albumin microspheres as a sustained drug delivery system for the antimetabolite, 5-fluorouracil. Artif Cells Blood Substit Immobil Biotechnol. 1995;23(5):579–586. doi: 10.3109/10731199509117972. [PubMed] [Cross Ref]
3. Arshady R. Albumin microspheres and microcapsules: methodology of manufacturing techniques. J Control Release. 1990;14:111–131. doi: 10.1016/0168-3659(90)90149-N. [Cross Ref]
4. Burger JJ, Tomlinson E, Mulder EMA, McVie JG. Albumin microspheres for intra-arterial tumour targeting, I: pharmaceutical Aspects. Int J Pharm. 1985;23:333–344. doi: 10.1016/0378-5173(85)90160-7. [Cross Ref]
5. Zeng XM, Martin GP, Marriott C. Albumin microspheres as a means of drug delivery to the lung: analysis of the effects of process variables on particle sizes using factorial design methodology. Int J Pharm. 1994;107:205–210. doi: 10.1016/0378-5173(94)90435-9. [Cross Ref]
6. Ishizaka T, Endo K, Koishi M. Preparation of egg albumin microcapsules and micropheres. J Pharm Sci. 1981;70(4):353–363. doi: 10.1002/jps.2600700404. [PubMed] [Cross Ref]
7. Chabner BA, Allegra CJ, Curt GA, Calabresi P. Antineoplastic agents. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, ed. Goodman & Gilmans The Pharmacological Basis of Therapeutics. 9th ed. McGraw Hill; 1955:1233–1288.
8. Kumar V, Banker GS. Target-oriented drug delivery systems. In: Banker GS, Rhodes CT, editors. Modern Pharmaceutics. 3rd ed. New York, NY: Marcel Dekker; 1995. pp. 611–680.
9. Truter EJ, Santos AS, Els WJ. Assessment of the antitumour activity of targeted immunospecific albumin microspheres loaded with cisplatin and 5-fluouracil: toxicity against a rodent ovarian carcinoma in vitro. Cell Biol Int. 2001;25(1):51–59. doi: 10.1006/cbir.2000.0677. [PubMed] [Cross Ref]
10. Gupta PK, Hung CT, Lam FC, Perrier DG. Albumin microspheres, III: synthesis and characterization of microspheres containing adriamycin and magnetite. Int J Pharm. 1988;43:167–177. doi: 10.1016/0378-5173(88)90072-5. [Cross Ref]
11. Sheu MT, Moustafa MA, Sokoloski TD. Entrapment of bioactive compound within native albumin beads, II: effect of rate and extent of cross linking on microbead properties. J Parent Sci Tech. 1986;40(6):253–258. [PubMed]
12. Karunakaran S, Singh J. Preparation, characterization and in vitro release kinetics of salbutamol sulphate loaded albumin microspheres. Drug Dev Ind Pharm. 1994;20(8):1377–1399. doi: 10.3109/03639049409038377. [Cross Ref]
13. Gallo JM, Hung CT, Perrier DG. Analysis of albumin microsphere preparation. Int J Pharm. 1984;22:63–74. doi: 10.1016/0378-5173(84)90046-2. [Cross Ref]
14. Yapel AF. Albumin microspheres: heat and chemical stabilization. Methods in Enzymology. 1985;112:3–18. doi: 10.1016/S0076-6879(85)12003-3. [PubMed] [Cross Ref]
15. Kim CK, Oh YK. Development of hydrophilic human serum albumin microspheres using a drug-albumin conjugate. Int J Pharm. 1988;47:163–169. doi: 10.1016/0378-5173(88)90227-X. [Cross Ref]
16. Gupta PK, Hung CT, Perrier DG. Albumin microspheres, I: release characteristics of adriamycin. Int J Pharm. 1986;33:137–146. doi: 10.1016/0378-5173(86)90047-5. [Cross Ref]
17. Gupta PK, Hung CT, Perrier DG. Albumin microspheres, II: effect of stabilization temperature on the release of adriamycin. Int J Pharm. 1986;33:147–153. doi: 10.1016/0378-5173(86)90048-7. [Cross Ref]
18. Bertucci C, Ascoli G, Uccello-Barretta G, Bari L, Salvadori P. The binding of 5-fluorouracil to native and modified human serum albumin: UV, CD, and 1H and 19F NMR investigation. J Pharm Biomed Anal. 1995;13(9):1087–1093. doi: 10.1016/0731-7085(95)01548-Y. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists